Entero Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Entero Therapeutics has a total shareholder equity of $70.8M and total debt of $177.6K, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are $86.3M and $15.5M respectively.
Key information
0.3%
Debt to equity ratio
US$177.56k
Debt
Interest coverage ratio | n/a |
Cash | US$662.48k |
Equity | US$70.80m |
Total liabilities | US$15.49m |
Total assets | US$86.29m |
Recent financial health updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31Financial Position Analysis
Short Term Liabilities: ENTO's short term assets ($84.4M) exceed its short term liabilities ($15.4M).
Long Term Liabilities: ENTO's short term assets ($84.4M) exceed its long term liabilities ($101.0K).
Debt to Equity History and Analysis
Debt Level: ENTO has more cash than its total debt.
Reducing Debt: ENTO's debt to equity ratio has reduced from 64.5% to 0.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENTO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ENTO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.1% each year